IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
Fiche publication
Date publication
décembre 2021
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno, Pr WESTEEL Virginie
Tous les auteurs :
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N
Lien Pubmed
Résumé
Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC).
Mots clés
chemotherapy, immunotherapy, lung cancer, non-small-cell lung cancer, real-life evidence, sequence
Référence
ESMO Open. 2021 Dec 22;7(1):100353